JAVIER
SASTRE VALERA
Profesor asociado de Ciencias de la Salud
Hospital General Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (17)
2023
2022
-
SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 646-657
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
2020
2019
2018
2015
-
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: Clinical and biological features
BMC Cancer, Vol. 15, Núm. 1
-
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours
European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380
2014
-
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer
Annals of Oncology, Vol. 25, Núm. 1, pp. 216-225
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
-
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: Relationship between skin rash and survival (Pantar study)
Annals of Oncology, Vol. 23, Núm. 7, pp. 1919-1925
-
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
PLoS ONE, Vol. 7, Núm. 10
2011
-
Evaluación ecónomica de capecitabina + cisplatino frente a 5-FU + cisplatino en el tratamiento en primera línea de cáncer gástrico avanzado en España
Pharmacoeconomics - Spanish Research Articles, Vol. 8, Núm. 2, pp. 51-58
2005
-
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5- fluorouracil for locally advanced squamous cell carcinoma of the head and neck: A randomised phase II study
European Journal of Cancer, Vol. 41, Núm. 9, pp. 1254-1260
-
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study
Journal of Clinical Oncology, Vol. 23, Núm. 15, pp. 3545-3551